



---

Original article

# NeoPeptide: an immunoinformatic database of T-cell-defined neoantigens

Wei-Jun Zhou<sup>1,†</sup>, Zhi Qu<sup>2,†</sup>, Chao-Yang Song<sup>1</sup>, Yang Sun<sup>3</sup>, An-Li Lai<sup>3</sup>,  
Ma-Yao Luo<sup>3</sup>, Yu-Zhe Ying<sup>3</sup>, Hu Meng<sup>3</sup>, Zhao Liang<sup>1</sup>, Yan-Jie He<sup>1</sup>,  
Yu-Hua Li<sup>1,\*</sup> and Jian Liu<sup>4,\*</sup>

<sup>1</sup>Department of Hematology, Zhujiang Hospital, Southern Medical University, 253 Industrial Avenue, Haizhu, Guangzhou 510282, China, <sup>2</sup>School of Computer Science and Technology, Harbin Institute of Technology, 92 West Dazhi Street, Nan Gang District, Harbin 150001, China, <sup>3</sup>The Second Clinical Medical College (Zhujiang Hospital), Southern Medical University, 253 Industrial Avenue, Haizhu, Guangzhou 510282, China, and <sup>4</sup>College of Computer Science, NanKai University, No.38 Tongyan Road, Jinnan District, Tianjin 300350, China

\*Corresponding author: Tel: +86 020 61643190; Email: jianliu@hit.edu.cn

†These authors contributed equally to this work.

Citation details: Zhou, W.-J., Qu, Z., Song, C.-Y. *et al.* NeoPeptide: an immunoinformatic database of T-cell-defined neoantigens. *Database* (2019) Vol. 2019: article ID baz128; doi:10.1093/database/baz128

\*Correspondence may also be addressed to Yu-Hua Li. Tel: +86 020 61643188; Email: liyuhua2011gz@163.com

Received 18 December 2018; Revised 11 October 2019; Accepted 15 October 2019

## Abstract

Therapeutic vaccines represent a promising immunotherapeutic modality against cancer. Discovery and validation of antigens is the key to develop effective anti-cancer vaccines. Neoantigens, arising from somatic mutations in individual cancers, are considered as ideal cancer vaccine targets because of their immunogenicity and lack of expression in normal tissues. However, only few databases support convenient access to these neoantigens for use in vaccines. To address this gap, we developed a web-accessible database, called NeoPeptide, which contains most of the important characteristics of neoantigens (such as mutation site, subunit sequence, major histocompatibility complex restriction) derived from published literature and other immunological resources. NeoPeptide also provides links to resources for further characterization of the novel features of these neoantigens. NeoPeptide will be regularly updated with newly identified and published neoantigens. Our work will help researchers in identifying neoantigens in different cancers and hasten the search for appropriate cancer vaccine candidates.

**Database URL:** [www.neopeptide.cn](http://www.neopeptide.cn) or <https://github.com/lyotvincent/NeoPeptide>

---

## Introduction

The ability of the immune system to recognize cancerous cells has opened the door for the development of cancer

© The Author(s) 2019. Published by Oxford University Press.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

immunotherapy. Anti-cancer vaccines represent one of the most promising immunotherapeutic modalities against cancer. An ideal vaccine would harness the immune system

Page 1 of 6

for the selective destruction of cancer cells while having no adverse effect on normal tissues. Traditionally, anti-cancer vaccines have targeted tumor-associated antigens (TAAs), which are produced by genes overexpressed in cancer cells, such as Survivin (1), gp100 (2), WT1 (3), HER2/Neu (4) and MUC1 (5). These TAA-based vaccines have been shown to induce specific T responses *in vitro*; however, robust evidence of their long-term efficacy in cancer patients is yet to be obtained (6). A key limiting factor is that TAAs are also expressed in normal cells or germline tissues, although at low levels. This prevents an effective immune response due to central immune tolerance; contrarily, a strong immune response against these antigens may result in autoimmunity (7, 8).

Unlike TAAs, neoantigens, arising from somatic mutations, are expressed only on tumor cells (9). In this context, neoantigens may not be subject to immune tolerance and pose a lower risk of inducing autoimmunity; thus, these are considered as ideal cancer vaccine targets. However, translation of a somatic mutation into a neoantigen-based vaccine would entail at least four steps: (i) prediction of somatic nucleic acid exchange, (ii) identification of mutated proteins and the corresponding amino acid exchange, (iii) human leukocyte antigen (HLA) typing of patients and (iv) screening of the mutated peptide sequences with high affinity to HLA/MHC (major histocompatibility complex) molecules. The time required for these steps greatly reduces the work efficiency and limits the clinical utility (10–12). Therefore, there is a need to establish a database that catalogs the verified neoantigens and provides an effective search functionality to recognize neoepitopes as soon as a novel somatic mutation is defined (13–15). Previously developed databases have compiled a vast repertoire of traditional TAAs and largely ignored the importance of gathering epitopes derived from neoantigens [e.g. the AntiJen database ([http://www.ddg-](http://www.ddg-pharmfac.net/antijen/AntiJen/antijenhomepage.htm)

[pharmfac.net/antijen/AntiJen/antijenhomepage.htm](http://www.ddg-pharmfac.net/antijen/AntiJen/antijenhomepage.htm)) (16)] or show the neoepitopes predicted from The Cancer Genome Atlas (TCGA) and the TCIA database (<https://tcia.at/home>) (17) [e.g. the TSNAdb database (<http://biopharm.zju.edu.cn/tsnadb/>) (18)] or are based on experimental data [e.g. the IEDB database (<http://www.iedb.org/>) (19)] or mostly focus on peptides identified previously [e.g. the CAPEd database (<https://caped.icp.ucl.ac.be/>)]. Here, we introduce NeoPeptide, a web-based database, which provides access to search facility for neoantigens in the context of different cancers. NeoPeptide not only helps characterize the newly identified neoantigens (such as sequence, MHC restriction, adjuvant] but also provides additional information such as the corresponding nucleic acid and amino acid exchange in each neoepitope. In addition, NeoPeptide provides a way to further discover new characteristics of these neoepitopes.

## Materials and Methods

### Database implementation

The NeoPeptide database was built using tomcat 9.0.7 (web server) and MySQL (database server). All data were processed and organized into a MySQL database management system (version 5.7.20). The framework of the website was designed and implemented using the Java Spring MVC and the user interface was developed using html, css and jQuery libraries. The website has been tested using several web browsers, including Internet Explorer (e.g. version 11.648.17134.0), Google Chrome (e.g. version 73.0.3683.86) and Firefox (e.g. version 60.0.2).

### System architecture

A schematic illustration of the system architecture is shown in Figure 1. As this is a web-based application, users are




Figure 1. Structure of the neopeptide system.

not required to install complex software. In addition, a single browser is needed for searching and downloading the data.

### Search functionality

The search functionality has two modes. The first mode is the fuzzy search mode for general users, wherein users input a keyword to retrieve the related items. The web application sorts the retrieved items by priority, since the rules matching all fields may lead to a large amount of data. Therefore, we introduced the Levenshtein distance to help users quickly identify the data items of interest. The second mode is the advanced search mode wherein the advanced users can search for terms according to specific fields such as gene, neoantigen, amino acid exchange, HLA allele or peptide. Furthermore, there are three Boolean operators

(AND, OR and NOT) to combine or exclude keywords for more focused results. The Boolean operator AND is the default mode; however, the users can alter the functionality using a pull-down menu.

### Download in NeoPeptide

The original data of NeoPeptide is freely available for download in the .dbf and \*.xlsx formats. The .dbf file extension represents the dBase database file, and this format is supported by a number of database products. After downloading this file, users can import the data in their own database systems via the database import wizard function. For instance, users can use the database development tool Navicat (<https://www.navicat.com/en/products/navicat-for-mysql>), which incorporates the import wizard function for importing the .dbf file into a database system.

The screenshot shows the NeoPeptide website interface. At the top left is the logo 'NeoPeptide' with the URL 'www.NeoPeptide.cn'. At the top right are navigation links: 'Home', 'Search', 'Download', and 'Contact'. Below the navigation is a dark grey header with the text 'Search Data'. Underneath is a search bar with 'KRAS' entered and a search icon. Below the search bar are two tabs: 'Q Search' (selected) and 'Advanced'. The main content area displays a table of search results for 'KRAS'. The table has 9 columns: Cancer, Gene, Neoantigen, Nucleic Acid Exchange, Amino Acid Exchange, HLA/MHC Allele, length, peptide, and journalRef. The results list various cancer types (Melanoma, Pancreatic Cancer, Thymoma, Endometrial Cancer) and their corresponding gene mutations (KRAS G12D, KRAS G13D, KRAS G12V, KRAS G12C, KRAS G12R, KRAS G12A) and associated HLA alleles. At the bottom of the table is a pagination control showing 'Total 76 Records', page numbers 1, 2, 3 (selected), 4, and a 'Go to page' field with '3' entered.

Cancer	Gene	Neoantigen	Nucleic Acid Exchange	Amino Acid Exchange	HLA/MHC Allele	length	peptide	journalRef
Melanoma	KRAS	KRAS F156L	468T>G	F156L	HLA-A*32:01	9	RVEDA <sup>L</sup> LYTL	SCIENCE 350: 207-211.
Melanoma	KRAS	KRAS F156L	468T>G	F156L	HLA-A*32:01	9	ALYTLVREI	SCIENCE 350: 207-211.
Melanoma	KRAS	KRAS F156L	468T>G	F156L	HLA-A*02:01	9	RVEDA <sup>L</sup> LYTL	SCIENCE 350: 207-211.
Melanoma	KRAS	KRAS F156L	468T>G	F156L	HLA-A*02:01	9	ALYTLVREI	SCIENCE 350: 207-211.
Pancreatic Cancer	KRAS	KRAS G12D	NA	G12D	HLA-DRB1*07:01	15	MTEYKLVVVGAD <sup>G</sup> GVG	J CLIN INVEST 2019:130
Thymoma	KRAS	KRAS G12D	NA	G12D	HLA-A*02:01	10	KLVVVGAD <sup>G</sup> GV	J CLIN INVEST 2019:130
Thymoma	KRAS	KRAS G13D	NA	G13D	HLA-A*02:01	8	VVVGAG <sup>D</sup> V	J CLIN INVEST 2019:130
Thymoma	KRAS	KRAS G13D	NA	G13D	HLA-A*02:01	10	KLVVVGAG <sup>D</sup> V	J CLIN INVEST 2019:130
Thymoma	KRAS	KRAS G12V	NA	G12V	HLA-A*02:01	10	KLVVVGAY <sup>G</sup> GV	J CLIN INVEST 2019:130
Thymoma	KRAS	KRAS G12C	NA	G12C	HLA-A*02:01	10	KLVVVGAC <sup>G</sup> GV	J CLIN INVEST 2019:130
Thymoma	KRAS	KRAS G12R	NA	G12R	HLA-A*02:01	10	KLVVVGAR <sup>G</sup> GV	J CLIN INVEST 2019:130
Pancreatic Cancer	KRAS	KRAS G12D	NA	G12D	HLA-A*1101	9	VVGA <sup>D</sup> GVGK	J CLIN INVEST 2019:130
Endometrial Cancer	KRAS	KRAS G12C	NA	G12C	HLA-A*1101	9	VVGA <sup>C</sup> GVGK	J CLIN INVEST 2019:130
Pancreatic Cancer	KRAS	KRAS G12V	NA	G12V	HLA-A*0201	10	KLVVVGAY <sup>G</sup> GV	J CLIN INVEST 2019:130
Pancreatic Cancer	KRAS	KRAS G12V	NA	G12V	HLA-A*0201	10	KLVVVGAY <sup>G</sup> GV	J CLIN INVEST 2019:130
Lung Cancer	KRAS	KRAS G12A	NA	G12A	HLA-A*1101	9	VVGA <sup>A</sup> GVGK	J CLIN INVEST 2019:130
Pancreatic Cancer	KRAS	KRAS G12V	NA	G12V	HLA-A*1101	9	VVGA <sup>V</sup> GVGK	J CLIN INVEST 2019:130
Pancreatic Cancer	KRAS	KRAS G12V	NA	G12V	HLA-A*0201	10	KLVVVGAY <sup>G</sup> GV	J CLIN INVEST 2019:130
Pancreatic Cancer	KRAS	KRAS G12D	NA	G12D	HLA-A*0201	10	KLVVVGAD <sup>G</sup> GV	J CLIN INVEST 2019:130
Pancreatic Cancer	KRAS	KRAS G12V	NA	G12V	HLA-A*1101	9	VVGA <sup>V</sup> GVGK	J CLIN INVEST 2019:130

Figure 2. Search result example of 'fuzzy search'. When the keyword 'KRAS' was searched, 76 entries were returned.

## Results

### Statistics of neoantigens in NeoPeptide

NeoPeptide is a comprehensive resource of somatic mutation-derived neoantigens. Neoantigens confirmed in cancer vaccines from clinical trials as well as *in vitro* experiments are recorded. Detailed information pertaining to the characteristics of the neoantigens is included in the database, such as HLA typing and corresponding nucleic acid and amino acid exchange.

NeoPeptide currently contains 181 137 epitopes derived from more than 36 000 neoantigens. These neoantigens have been defined in different cancers, including non-small cell lung cancer (e.g. *EGFR Q701L*), breast cancer (e.g. *TP53 S355F*), melanoma (e.g. *TMEM48 F169 L*), renal cell carcinoma (e.g. *ARMC8 T60I*), myeloproliferative neoplasms (e.g. *TET2 C784S*), gastric cancer (e.g. *BRCA2 S37 L*), uterine leiomyosarcoma (e.g. *SEC14L5 L289 V*), ovarian cancer (e.g. *ABCD2 E686Q*), pancreatic cancer (e.g. *MEN1 A68P*), colon cancer (e.g. *TP53 R175H*) and head and neck squamous cell carcinoma (e.g. *BRE S170 L*) and so on. In addition, NeoPeptide will be regularly updated to include newly identified and published neoantigens.

### Applications of NeoPeptide: a utility case

To facilitate database access, we developed a web interface that incorporates both simple and advanced search functionalities. For each entry, the main information includes ‘Cancer’ (the underlying disease from which the neoantigen was found), ‘Gene’ (the corresponding wild-type gene), ‘Neoantigen’, ‘Nucleic Acid Exchange’ (the nucleic acid somatic from the corresponding wild-type gene), ‘Amino Acid Exchange’ (the amino acid somatic from the corresponding wild-type gene), ‘HLA/MHC Allele’ (the HLA restriction of neoantigens used in the cancer vaccine), ‘Length’ (the length of neoantigen-derived epitopes used in the cancer vaccine), ‘Peptide’ (the sequence of neoantigen-derived epitopes) and ‘journalRef’ (publications that support the role of the neoantigen in cancer vaccine).

For demonstration purposes, the results of a fuzzy search ‘KRAS’ are shown in Figure 2. The database search retrieved 76 entries that have been experimentally identified or predicted as subunits in vaccines against melanoma, pancreatic cancer, thymoma or lung cancer. In the advanced search mode with restrictions of ‘melanoma’ and ‘KRAS’, 12 entries were retrieved (Figure 3). These results indicate that these 12 peptides may apply to neoantigen vaccine

The screenshot shows the NeoPeptide website interface. At the top, there is a navigation bar with 'Home', 'Search', 'Download', and 'Contact'. The main content area is titled 'Search Data'. Below this, there is a search form with two tabs: 'Search' and 'Advanced'. The 'Advanced' tab is selected. The search criteria are set to 'Cancer: melanoma' and 'Gene: KRAS'. There are 'Reset' and 'Search' buttons. Below the search form is a table with 12 rows of search results. The table columns are: Cancer, Gene, Neoantigen, Nucleic Acid Exchange, Amino Acid Exchange, HLA/MHC Allele, length, peptide, and journalRef. The results show 12 entries for Melanoma with the KRAS gene, each with a specific neoantigen, nucleic acid exchange, amino acid exchange, HLA/MHC Allele, length, peptide sequence, and journal reference.

Cancer	Gene	Neoantigen	Nucleic Acid Exchange	Amino Acid Exchange	HLA/MHC Allele	length	peptide	journalRef
Melanoma	KRAS	KRAS Q61H	183A>C	Q61H	HLA-C*16:02	10	ILDTAGHFEY	SCIENCE 350: 207-211.
Melanoma	KRAS	KRAS F156L	468T>G	F156L	HLA-C*02:02	10	RVEDA <sub>L</sub> YTLV	SCIENCE 350: 207-211.
Melanoma	KRAS	KRAS F156L	468T>G	F156L	HLA-C*02:02	10	RVEDA <sub>L</sub> YTLV	SCIENCE 350: 207-211.
Melanoma	KRAS	KRAS F156L	468T>G	F156L	HLA-A*32:01	10	KTRQRVEDA <sub>L</sub>	SCIENCE 350: 207-211.
Melanoma	KRAS	KRAS F156L	468T>G	F156L	HLA-A*02:01	10	RVEDA <sub>L</sub> YTLV	SCIENCE 350: 207-211.
Melanoma	KRAS	KRAS F156L	468T>G	F156L	HLA-C*02:02	9	RVEDA <sub>L</sub> YTL	SCIENCE 350: 207-211.
Melanoma	KRAS	KRAS F156L	468T>G	F156L	HLA-C*02:02	9	RVEDA <sub>L</sub> YTL	SCIENCE 350: 207-211.
Melanoma	KRAS	KRAS F156L	468T>G	F156L	HLA-B*40:02	9	VEDA <sub>L</sub> YTLV	SCIENCE 350: 207-211.
Melanoma	KRAS	KRAS F156L	468T>G	F156L	HLA-A*32:01	9	RVEDA <sub>L</sub> YTL	SCIENCE 350: 207-211.
Melanoma	KRAS	KRAS F156L	468T>G	F156L	HLA-A*32:01	9	ALYTLVREI	SCIENCE 350: 207-211.
Melanoma	KRAS	KRAS F156L	468T>G	F156L	HLA-A*02:01	9	RVEDA <sub>L</sub> YTL	SCIENCE 350: 207-211.
Melanoma	KRAS	KRAS F156L	468T>G	F156L	HLA-A*02:01	9	ALYTLVREI	SCIENCE 350: 207-211.

At the bottom of the table, there is a pagination control showing 'Total 12 Records', '1' items per page, '20 Items per page' dropdown, 'Go to page 1', and a 'Go' button.

**Figure 3.** Search result example of ‘advanced search’. When the keywords ‘Melanoma’ and ‘KRAS’ were searched at the same time, 12 entries were returned.

targeting the corresponding mutated KRAS and that this neoantigen vaccine may be effective in patients with melanoma. In addition, on clicking the entries in the ‘Cancer’ or ‘Gene’ column, the user will be directed to the NCBI’s search page (<https://www.ncbi.nlm.nih.gov/search/>) that contains detailed information about the corresponding cancer or the wild-type gene, respectively. Similarly, on clicking the entries in the ‘Peptide’ column, the user is directed to the IEDB webpage (<http://tools.iedb.org/mhci/>) for more details about the affinity to HLA or MHC molecules of these neoantigen-derived epitopes (Supplement information). Clicking the ‘journalRef’ link will navigate the user directly to the NCBI’s journal page.

## Discussions

Most cancers are characterized by a number of somatic mutations; however, not all of these mutations are suitable targets for cancer vaccine. According to the clinical trials of neoantigen vaccine, translation of somatic mutations into neoantigens for use in vaccines typically requires a period of 1–2 months. As most patients with advanced cancers survive for no more than 3 months, this time-consuming work represents a major barrier to the clinical use of neoantigen vaccines. Here, we developed a user-friendly neoantigen database, which may help researchers in quickly selecting the peptides for potential use in neoantigen vaccines. Moreover, NeoPeptide also provides useful links for further research on the functions of neoantigens. This database will be regularly updated with newly identified neoantigens in the context of a wider range of cancers. Further development of NeoPeptide will continue in order to offer a more comprehensive collection of experimentally supported data.

Many previous works mainly focus on the peptide information retrieval using the deterministic keyword inputs; this may affect the search capabilities and data FAIRness. Some databases (e.g. IEDB) raise concerns about ontology usage in recent years and make promising changes to reach the FAIR principles, which make it more interoperable with other projects. According to this, we will iteratively use ontology into the user interface, especially for disease term search and ‘HLA/MHC Allele’ search and reach more goals of FAIRness (19, 20).

## Supplementary data

Supplementary data are available at Database Online.

## Acknowledgements

We gratefully acknowledge Jiao Chen, Xiaoxuan Feng, Shaofen Zhang, Zhiyong Chen, Rongrong Tan, Ruirong Chen and Baoyi Deng for collecting data from mining and cleaning data from literatures.

## Funding

National Key R&D Program of China (2018YFC1603800, 2018YFC1603802); National Natural Science Foundation of Guangdong Province (2017A030310301; 2019A1515010299); National Natural Science Foundation of China (61602130, 61872115); Science and Technology Plan Project of Guangzhou (201704020216); China Postdoctoral Science Foundation funded project (2016 T90294); Dean Fund on Clinical Research of Zhujiang Hospital, Southern Medical University; Research Startup Project of Southern Medical University (PY2016N009); Shanghai Municipal Science and Technology Major Project (2017SHZDZX01).

*Conflict of interest.* None declared.

## References

- Schmitz, M., Diestelkoetter, P., Weigle, B. *et al.* (2000) Generation of survivin-specific CD8+ T effector cells by dendritic cells pulsed with protein or selected peptides. *Cancer Res.*, **60**, 4845–4849.
- Kawakami, Y., Eliyahu, S., Jennings, C. *et al.* (1995) Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with *in vivo* tumor regression. *J. Immunol.*, **154**, 3961–3968.
- Ohnishi, H., Yasukawa, M. and Fujita, S. (2000) HLA class I-restricted lysis of leukemia cells by a CD8(+) cytotoxic T-lymphocyte clone specific for WT1 peptide. *Blood*, **95**, 286–293.
- Rongcun, Y., Salazar-Onfray, F., Charo, J. *et al.* (1999) Identification of new HER2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas. *J. Immunol.*, **163**, 1037–1044.
- Brossart, P., Heinrich, K.S., Stuhler, G. *et al.* (1999) Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. *Blood*, **93**, 4309–4317.
- Melero, I., Gaudernack, G., Gerritsen, W. *et al.* (2014) Therapeutic vaccines for cancer: an overview of clinical trials. *Nat. Rev. Clin. Oncol.*, **11**, 509–524.
- Rosenberg, S.A., Yang, J.C. and Restifo, N.P. (2004) Cancer immunotherapy: moving beyond current vaccines. *Nat. Med.*, **10**, 909–915.
- Purcell, A.W., McCluskey, J. and Rossjohn, J. (2007) More than one reason to rethink the use of peptides in vaccine design. *Nat. Rev. Drug Discov.*, **6**, 404–414.
- Aldous, A.R. and Dong, J.Z. (2018) Personalized neoantigen vaccines: a new approach to cancer immunotherapy. *Bioorg. Med. Chem.*, **26**, 2842–2849.
- Efremova, M., Finotello, F., Rieder, D. *et al.* (2017) Neoantigens generated by individual mutations and their role in cancer immunity and immunotherapy. *Front. Immunol.*, **8**, 1679.
- Carreno, B.M., Magrini, V., Becker-Hapak, M. *et al.* (2015) Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. *Science*, **348**, 803–808.
- Matsuda, T., Leisegang, M., Park, J.H. *et al.* (2018) Induction of neoantigen-specific cytotoxic T cells and construction of T-cell

- receptor-engineered T cells for ovarian cancer. *Clin. Cancer Res.*, **24**, 5357–5367.
13. Liu, J., Liu, Q., Zhang, L. *et al.* (2019) Enabling massive XML-based biological data management in HBase. *IEEE/ACM Trans. Comput. Biol. Bioinform.*, doi: 10.1109/TCBB.2019.2915811.
  14. Liu, J. and Yan, D. (2016) Answering approximate queries over XML data. *IEEE Trans. Fuzzy Syst.*, **24**, 288–305.
  15. Liu, J., Yang, M., Zhang, L. *et al.* (2019) An effective biomedical data migration tool from resource description framework to JSON. *Database (Oxford)*, doi: 10.1093/database/baz088.
  16. Toseland, C.P., Clayton, D.J., Mcsparron, H. *et al.* (2005) AntiJen: a quantitative immunology database integrating functional, thermodynamic, kinetic, biophysical, and cellular data. *Immunome Res.*, **1**, 4.
  17. Charoentong, P., Finotello, F., Angelova, M. *et al.* (2016) Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. *Cell Rep.*, **2017**, 248–262.
  18. Wu, J., Zhao, W., Zhou, B. *et al.* (2018) TSNAdb: a database for tumor-specific neoantigens from immunogenomics data analysis. *Genomics Proteomics Bioinformatics*, **16**, 276–282.
  19. Vita, R., Mahajan, S., Overton, J.A. *et al.* (2019) The immune epitope database (IEDB): 2018 update. *Nucleic Acids Res.*, **47**, D339–D343.
  20. Wilkinson, M.D., Dumontier, M., Aalbersberg, I.J. *et al.* (2016) The FAIR guiding principles for scientific data management and stewardship. *Sci Data*, **3**, 160018.